# Yuanyuan Xu

> Yuanyuan Xu is a structural biologist turned biotech founder who left the protein-crystallography bench at Tsinghua and Yale to build Cure Genetics (克睿基因), a Suzhou clinical-stage company chasing cell and gene therapies for solid tumors and genetic disease. She founded it in 2016, raised a $60M Series B in 2021, and bets on two homegrown platforms: an invariant-natural-killer-T cell therapy (AIMS CAR-NKT) and a directed-evolution engine for new AAV capsids (VELP).

- **Role:** Founder, Chairman & CEO at Cure Genetics (克睿基因)
- **Organizations:** Cure Genetics (克睿基因), Suzhou University
- **Nationality:** Chinese
- **Education:** Ph.D. (advised by Academician Rao Zihe), Tsinghua University, Department of Biology, Postdoctoral fellow, Yale University
- **Known for:** Founded and leads Cure Genetics, a clinical-stage cell and gene therapy biotech, Published 13 papers in journals including Nature, Nature Structural & Molecular Biology, and Molecular Cell, Raised roughly $88.9M total funding across Series A and Series B rounds

## Career timeline

- **pre-2016** — Ph.D. at Tsinghua University under Academician Rao Zihe; postdoctoral research at Yale on protein structure related to DNA damage, repair, and tumorigenesis
- **2016** — Founded Cure Genetics in Suzhou (July 2016), co-founded with chief scientist Yanni Lin
- **2018** — Raised $17M Series A led by Qiming Venture Partners, with CTS Capital and Ascendin Investment
- **2021** — Partnership with Boehringer Ingelheim (January 2021)
- **2021** — Closed $60M Series B (December 2021) to advance cell therapy candidates for hematological and solid tumors
- **2023** — Partnership with Frametact Limited (September 2023)

## Achievements

- Founded and leads Cure Genetics, a clinical-stage cell and gene therapy biotech
- Published 13 papers in journals including Nature, Nature Structural & Molecular Biology, and Molecular Cell
- Raised roughly $88.9M total funding across Series A and Series B rounds
- Built the AIMS CAR-NKT cell therapy platform and the VELP AAV directed-evolution platform
- Named Jiangsu Province Innovation and Entrepreneurship Talent, Gusu Innovation and Entrepreneurship Leading Talent, and Suzhou Industrial Park Science and Technology Leading Talent
- Holds a professorship at Suzhou University

## Latest updates

- **2023-09** — Cure Genetics entered a partnership with Frametact Limited
- **2021-12** — Closed $60M Series B to advance cell therapy candidates for hematological and solid tumors

## Links

- Website: https://curegenetics.com
- LinkedIn: http://www.linkedin.com/in/%e5%85%83%e5%85%83-%e5%be%90-80072980

---

Profile page: https://yespress.io/yuanyuan-xu
Published by YesPress — https://yespress.io
Last updated: 2026-06-04